Printer Friendly Version
Printer Friendly Version
Printer Friendly Version
L.7.01.430
Implantable infusion pumps can provide long-term drug infusion at constant or variable rates; several devices are commercially available.
An implantable infusion pump is intended to provide long-term continuous or intermittent drug infusion. Possible routes of administration include intravenous, intra-arterial, subcutaneous, intraperitoneal, intrathecal, and epidural. The implantable infusion pump is surgically placed in a subcutaneous pocket under the infraclavicular fossa or in the abdominal wall, and a catheter is threaded into the desired position. Intrathecal and epidural catheter positions are both intraspinal; however, the intrathecal position is located in the subarachnoid space, which is passed through the epidural space and dura mater and through the theca of the spinal cord.
A drug is infused over an extended period and may be delivered at a constant or variable rate by calibrating the implantable infusion pump per physician specifications. The drug reservoir may be refilled as needed by an external needle injection through a self-sealing septum in the implantable infusion pump. Bacteriostatic water or physiological saline is often used to dilute drugs. A heparinized saline solution may also be used during an interruption of drug therapy to maintain catheter patency.
The driving mechanisms may include peristalsis, fluorocarbon propellant, osmotic pressure, piezoelectric disk benders, or the combination of osmotic pressure with an oscillating piston.
Several implantable infusion pumps have been approved by the FDA through the premarket approval process, including, but not limited to, the SynchroMed® (Medtronic, Fridley, MN) family of pumps; the IsoMed® infusion system (Medtronic, Minneapolis, MN); the Prometra® programmable pump (Flowonix, Mount Olive, NJ); and Shiley Infusaid® pumps (Norwood, MA).
Baclofen for intrathecal injection was approved for an additional indication in 1996—for use with Medtronic’s implantable infusion pump in the treatment of spasticity of cerebral origin. The drug and pump were originally approved in 1992 for use in patients with severe spasticity of spinal origin. In 2012, the MedStream™ Programmable Infusion System (Codman and Shurtleff, a division of DePuy), which includes an implantable pump, was approved by the Food and Drug Administration through the premarket approval process for intrathecal delivery of baclofen in patients with spasticity.
On November 14, 2018, the FDA issued a safety communication: “Use Caution with Implanted Pumps for Intrathecal Administration of Medicines for Pain Management.” When considering a medicine for use in an implanted pump the communication recommends, in part, awareness of medicines not FDA approved for intrathecal administration or intrathecal implanted pump use (for example, hydromorphone, bupivacaine, fentanyl, clonidine). Further, the communication indicates that any mixture of two or more different kinds of medications as well as any compounded medications is not approved.
For Coding Guidelines see the Anesthesia Coding Policy .
Implantable infusion pumps are considered medically necessary when used to deliver drugs having FDA approval for this route of access and for the related indication for the treatment of:
Primary liver cancer (intrahepatic artery injection of chemotherapeutic agents)
Metastatic colorectal cancer where metastases are limited to the liver (intrahepatic artery injection of chemotherapeutic agents)
Primary epithelial ovarian cancer (intraperitoneal infusion as component of chemotherapy)
Severe, chronic, intractable pain (intravenous,intrathecal, and epidural injection of opioids) after a successful temporary trial of opioid or non-opioid analgesics by the same route of administration as the planned treatment. A successful trial is defined as greater than 50% reduction in pain after implementation of treatment.
Severe spasticity of cerebral or spinal cord origin in patients who are unresponsive to or who cannot tolerate oral baclofen therapy (intrathecal injection of baclofen)
Patients with insulin-dependent (type 1) diabetes mellitus who have not achieved adequate glycemic control with intensive SC insulin therapy via MDI or external insulin pump
Patients with insulin-requiring non-insulin-dependent (type 2) diabetes mellitus who have not achieved adequate glycemic control with intensive SC insulin therapy via MDI or external insulin pump
Implantable infusion pumps are considered investigational for all other uses (e.g., chemotherapy for patients with head and neck cancers or gastric cancer, heparin for thromboembolic disease, antibiotics for osteomyelitis).
Federal Employee Program (FEP) may dictate that all FDA-approved devices, drugs or biologics may not be considered investigational and thus these devices may be assessed only on the basis of their medical necessity.
The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language.
Medically Necessary is defined as those services, treatments, procedures, equipment, drugs, devices, items or supplies furnished by a covered Provider that are required to identify or treat a Member's illness, injury or Mental Health Disorders, and which Company determines are covered under this Benefit Plan based on the criteria as follows in A through D:
A. consistent with the symptoms or diagnosis and treatment of the Member's condition, illness, or injury; and
B. appropriate with regard to standards of good medical practice; and
C. not solely for the convenience of the Member, his or her Provider; and
D. the most appropriate supply or level of care which can safely be provided to Member. When applied to the care of an Inpatient, it further means that services for the Member's medical symptoms or conditions require that the services cannot be safely provided to the Member as an Outpatient.
For the definition of medical necessity, “standards of good medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, and physician specialty society recommendations, and the views of medical practitioners practicing in relevant clinical areas and any other relevant factors. BCBSMS makes no payment for services, treatments, procedures, equipment, drugs, devices, items or supplies which are not documented to be Medically Necessary. The fact that a Physician or other Provider has prescribed, ordered, recommended, or approved a service or supply does not in itself, make it Medically Necessary.
7/1993: Approved by Medical Policy Advisory Committee (MPAC).
11/1997: Revision approved by MPAC.
8/2001: Reviewed by MPAC; expanded indications to provide coverage of insulin (via implantable infusion pump) for diabetes.
2/13/2002: Investigational definition added.
5/1/2002: Type of Service and Place of Service deleted.
5/28/2002: Code Reference section updated, HCPCS code A4222 deleted.
3/6/2003: Code Reference section updated, code ranges 36260-36262, 36530-36532, 62350-62368, E0782-E0783 listed separately.
8/20/2003: ICD-9 diagnosis code range 140.0-49.9, 160.0-160.8, 190.0-190.9, 191.0-191.9, 192.0-192.9, 342.0-342.92, 344.3-344.32, 344.4-344.5, 344.8-344.89 listed separately.
1/6/2004: Code Reference section updated, ICD-9 procedure code 38.91, 38.93 deleted, ICD-9 diagnosis codes 155.2, 342.00, 342.01, 342.02, 342.80, 342.81, 342.82, 342.90, 342.91, 342.92, 344.2, 344.30, 344.31, 344.32, 344.40, 344.41, 344.42, 344.5 deleted.
10-25-2005: Code Reference section updated: CPT codes 36530, 36531, 36532 deleted from covered codes, CPT codes 36563, 36576, 36578, 36590, 95991 added to covered codes, ICD9 Diagnosis code ranges revised, ICD9 Diagnosis codes 250.00 - 250.90, 250.03 - 250.93 added, HCPCS code S9328 added.
03/10/2006: Coding updated: CPT4 2006 revisions added to policy.
7/18/2008: Anesthesia Coding Policy hyperlink added.
9/28/2009: Coding Section updated with New ICD-9 Diagnosis codes for 10-1-2009 under Covered Codes Table- 209.31, 209.32, Verbiage added to Covered Codes Table, "*Some covered procedure codes may have multiple descriptions. Coverage will only be made for covered codes when used for services outlined within the policy statement section."
10/6/2009: Coding reference section updated. New ICD-9 code 209.72 added to covered table.
08/12/2010: Policy description updated regarding available devices. The policy statement regarding implantable infusion pumps for severe, chronic, intractable pain was revised to indicate that it is only considered medically necessary following a successful trial, defined as at least a 50% reduction in pain, of spinal (epidural or intrathecal) opioid or non-opioid analgesics. FEP verbiage added to the Policy Exceptions section.
11/10/2011: In the medically necessary policy statement for severe, chronic, intractable pain, added "by the same route of administration as the planned treatment" to the policy statement.
04/18/2013: Primary epithelial ovarian cancer (intraperitoneal infusion as component of chemotherapy) added to policy statement as medically necessary. Policy statement revised to delete the following from the medically necessary policy statement: Head/neck cancers (intra-arterial injection of chemotherapeutic agents). Added the following to the investigational policy statement: chemotherapy for patients with head and neck cancers or gastric cancer. Added ICD-9 codes 183.0 - 183.9 to the Code Reference section.
03/07/2014: Policy reviewed; no changes.
08/31/2015: Code Reference section updated for ICD-10. Removed ICD-9 procedure codes 03.02, 03.90, and 86.09.
06/09/2016: Policy number L.7.01.430 added. Policy Guidelines updated to add medically necessary definition.
09/30/2016: Code Reference section updated to add the following new ICD-10 diagnosis codes: E11.3521 - E11.3529, E11.3531 - E11.3539, E11.3541 - E11.3549, E11.37X1 - E11.37X9, E13.37X1 - E13.37X9, E10.3521 - E10.3529, E10.3531 - E10.3539, E10.3541 - E10.3549, and E10.37X1 - E10.37X9.
12/30/2016: Code Reference section updated to add new 2017 HCPCS code A4224. Revised code description for HCPCS code A4221.
09/29/2017: Code Reference section updated to add new ICD-10 diagnosis codes E11.10 and E11.11. Effective 10/01/2017.
08/09/2018: Policy description updated regarding possible routes of administration and FDA-approved devices. Medically necessary criteria updated to add "trial" to the third statement.
09/24/2018: Code Reference section updated to add new ICD-10 diagnosis codes D04.111, D04.112, D04.121, and D04.122, effective 10/01/2018.
05/31/2019: Policy description updated regarding a safety communication issued by the FDA. Policy statements unchanged.
05/02/2023: Policy reviewed. Policy statements unchanged. Policy Exceptions updated to remove statement regarding implantable infusion pumps for FEP members. Policy Guidelines updated to change "Nervous/Mental Conditions" to "Mental Health Disorders" and "Medically Necessary" to "medical necessity." Code Reference section updated to remove deleted ICD-10 diagnosis codes D04.11 and D04.12.
04/30/2024: Policy reviewed; no changes.
08/01/2025: Policy reviewed; no changes.
10/01/2025: Code Reference section updated to add new ICD-10 diagnosis codes G35.A, G35.B0, G35.B1, G35.B2, G35.C0, G35.C1, G35.C2, and G35.D.
A search of literature was completed through the MEDLINE database for the period of January 1992 through December 1995. The search strategy focused on references containing the Medical Subject Heading; Infusion Pumps, Implantable. Research was limited to English-language journals on humans.
Blue Cross Blue Shield Association policy # 7.01.41
Hayes Medical Technology Directory
Technology Evaluation and Coverage 1986: p. 135
Technology Evaluation and Coverage 1988: p. 150
This may not be a comprehensive list of procedure codes applicable to this policy.
The code(s) listed below are ONLY medically necessary if the procedure is performed according to the "Policy" section of this document.
For Coding Guidelines see the Anesthesia Coding Policy .
Code Number | Description | ||
CPT-4 | |||
36260 | Insertion of implantable intra-arterial infusion pump (eg, for chemotherapy of liver) | ||
36261 | Revision of implanted intra-arterial infusion pump | ||
36262 | Removal of implanted intra-arterial infusion pump | ||
36563 | Insertion of tunneled centrally inserted central venous access device with subcutaneous pump | ||
36576 | Repair of central venous access device, with subcutaneous port or pump, central are peripheral insertion site | ||
36578 | Replacement, catheter only, of central venous access device, with subcutaneous port or pump, central or peripheral insertion site | ||
36590 | Removal of tunneled central venous access device, with subcutaneous port or pump, central or peripheral insertion | ||
61215 | Insertion of subcutaneous reservoir, pump, or continuous infusion system for connection to ventricular catheter | ||
62350 | Implantation, revision or repositioning of tunneled intrathecal or epidural catheter, for long-term medication administration via an external pump or implantable reservoir/infusion pump; without laminectomy | ||
62351 | Implantation, revision or repositioning of tunneled intrathecal or epidural catheter, for long-term medication administration via an external pump or implantable reservoir/infusion pump; with laminectomy | ||
62355 | Removal of previously implanted intrathecal or epidural catheter | ||
62360 | Implantation or replacement of device for intrathecal or epidural drug infusion; subcutaneous reservoir | ||
62361 | Implantation or replacement of device for intrathecal or epidural drug infusion; non-programmable pump | ||
62362 | Implantation or replacement of device for intrathecal or epidural drug infusion; programmable pump, including preparation of pump, with or without programming | ||
62365 | Removal of subcutaneous reservoir or pump, previously implanted for intrathecal or epidural infusion | ||
62367 | Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); without reprogramming | ||
62368 | Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming | ||
95990 | Refilling and maintenance of implantable pump or reservoir for drug delivery, spinal (intrathecal, epidural) or brain (intraventricular) | ||
95991 | Refilling and maintenance of implantable pump or reservoir for drug delivery, spinal (intrathecal, epidural) or brain (intraventricular); administered by physician | ||
96522 | Refilling and maintenance of implantable pump or reservoir for drug delivery, systemic (eg, intravenous, intra-arterial) | ||
HCPCS | |||
A4220 | Refill kit for implantable infusion pump | ||
A4221 | Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately) | ||
A4224 | Supplies for maintenance of insulin infusion catheter, per week | ||
E0782 | Infusion pump, implantable, non-programmable (includes all components, e.g., pump, catheter, connectors, etc.) | ||
E0783 | Infusion pump system, implantable, programmable (includes all components, e.g., pump, catheter, connectors, etc.) | ||
E0785 | Implantable intraspinal (epidural/intrathecal) catheter used with implantable infusion pump, replacement | ||
E0786 | Implantable programmable infusion pump, replacement (excludes implantable intraspinal catheter) | ||
S9328 | Home infusion therapy, implanted pump pain management infusion; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem | ||
ICD-9 Procedure | ICD-10 Procedure | ||
86.06 | Insertion of totally implantable infusion pump | 0JH60VZ, 0JH63VZ | Insertion of infusion pump into chest subcutaneous tissue and fascia, by approach |
0JH70VZ, 0JH73VZ | Insertion of infusion pump into back subcutaneous tissue and fascia, by approach | ||
0JH80VZ, 0JH83VZ | Insertion of infusion pump into abdomen subcutaneous tissue and fascia, by approach | ||
ICD-9 Diagnosis | ICD-10 Diagnosis | ||
140.0 - 140.9 | Malignant neoplasm of lip code range | C00.0 - C00.9 | Malignant neoplasm of lip code range |
141.0 - 141.9 | Malignant neoplasm of tongue code range | C01, C02.0 - C02.9 | Malignant neoplasm of tongue code range |
142.0 -142.9 | Malignant neoplasm of major salivary glands code range | C07, C08.0 - C08.9 | Malignant neoplasm of parotid gland and other and unspecified major salivary glands code range |
143.0 -143.9 | Malignant neoplasm of gum code range | C03.0 - C03.9 | Malignant neoplasm of gum code range |
144.0 - 144.9 | Malignant neoplasm of floor of mouth code range | C04.0 - C04.9 | Malignant neoplasm of floor of mouth code range |
145.0 - 145.9 | Malignant neoplasm of other and unspecified parts of mouth code range | C05.0 - C06.9 | Malignant neoplasm of other and unspecified parts of mouth code range |
146.0 - 146.9 | Malignant neoplasm of oropharynx code range | C09.0 - C09.9, C10.0 - C10.9 | Malignant neoplasm of tonsil and oropharynx code range |
147.0 - 147.9 | Malignant neoplasm of nasopharynx code range | C11.0 - C11.9 | Malignant neoplasm of nasopharynx code range |
148.0 -148.9 | Malignant neoplasm of hypopharynx code range | C12, C13.0 - C13.9 | Malignant neoplasm of pyriform sinus and hypopharynx code range |
149.0, 149.1, 149.8, 149.9 | Malignant neoplasm of other and ill-defined sites within the lip and oral cavity, and pharynx code range | C14.0 - C14.8 | Malignant neoplasm of other and ill-defined sites within the lip and oral cavity, and pharynx code range |
154.0 | Malignant neoplasm rectosigmoid junction | C19 | Malignant neoplasm rectosigmoid junction |
155.0 | Malignant neoplasm liver, primary | C22.0, C22.2 - C22.8 | Malignant neoplasm liver, primary |
160.0 -160.9 | Malignant neoplasm of nasal cavities, middle ear, and accessory sinuses code range | C30.0 - C30.1, C31.0 - C31.9 | Malignant neoplasm of nasal cavity, middle ear, and accessory sinuses code range |
170.0, 170.1 | Malignant neoplasm of bones of skull and face code range | C41.0, C41.1 | Malignant neoplasm of bones of skull and face code range |
171.0 | Malignant neoplasm of connective and other soft tissue of head, face, and neck | C47.0, C49.0 | Malignant neoplasm of peripheral nerves and autonomic nervous system |
172.0 - 172.4 | Malignant melanoma of skin of head, face and neck code range | C43.0 - C43.4, D03.0 - D03.4 | Malignant melanoma and melanoma in situ of skin of head, face and neck code range |
173.0 - 173.4 | Other malignant neoplasm of skin of head, face and neck code range | C44.00 - C44.49 | Other malignant neoplasm of skin of head, face and neck code range |
183.0 - 183.9 | Malignant neoplasm of ovary and other uterine adnexa code range | C56.1 – C56.9 | Malignant neoplasm of ovary |
C57.00 – C57.02 | Malignant neoplasm of fallopian tube | ||
C57.10 – C57.12 | Malignant neoplasm of broad ligament | ||
C57.20 – C57.21 | Malignant neoplasm of round ligament | ||
C57.3 | Malignant neoplasm of parametrium | ||
C57.4 | Malignant neoplasm of uterine adnexa, unspecified | ||
190.0 - 190.9 | Malignant neoplasm of eye code range | C69.00 - C69.92 | Malignant neoplasm of eye and adnexa code range |
191.0 - 191.9 | Malignant neoplasm of brain code range | C71.0 - C71.9 | Malignant neoplasm of brain code range |
192.0 | Malignant neoplasm of cranial nerves | C72.20 – C72.22 | Malignant neoplasm of olfactory nerve |
C72.30 – C72.32 | Malignant neoplasm of optic nerve | ||
C72.40 – C72.42 | Malignant neoplasm of acoustic nerve | ||
C72.50 – C72.59 | Malignant neoplasm of other and unspecified cranial nerves | ||
192.1 | Malignant neoplasm of cerebral meninges | C70.0, C70.9 | Malignant neoplasm of meninges |
192.2 | Malignant neoplasm of spinal cord | C72.0, C72.1 | Malignant neoplasm of spinal cord and cauda equina |
192.3 | Malignant neoplasm of spinal meninges | C70.1 | Malignant neoplasm of spinal meninges |
192.8 | Malignant neoplasm of other specified sites of nervous system | C72.9 | Malignant neoplasm of central nervous system, unspecified |
192.9 | Malignant neoplasm of nervous system, part unspecified | ||
195.0 | Malignant neoplasm head, face, and neck | C76.0 | Malignant neoplasm head, face, and neck |
196.0 | Secondary and unspecified malignant neoplasm of lymph nodes of head, face, and neck | C77.0 | Secondary and unspecified malignant neoplasm of lymph nodes of head, face, and neck |
197.7 | Malignant neoplasm, liver specified as secondary | C78.7 | Secondary malignant neoplasm of liver and intrahepatic bile duct |
198.2 | Secondary malignant neoplasm of skin | C79.2 | Secondary malignant neoplasm of skin |
198.3 | Secondary malignant neoplasm of brain and spinal cord | C79.31 | Secondary malignant neoplasm of brain |
198.4 | Secondary malignant neoplasm of other parts of nervous system | C79.32, C79.40 - C79.49 | Secondary malignant neoplasm of cerebral meninges and other parts of nervous system |
198.89 | Secondary malignant neoplasm of other specified sites | C79.89, C79.9 | Secondary malignant neoplasm of other specified and unspecified sites |
209.31 | Merkel cell carcinoma of the face | C4A.0 - C4A.39 | Merkel cell carcinoma of the face |
209.32 | Merkel cell carcinoma of the scalp and neck | C4A.4 | Merkel cell carcinoma of the scalp and neck |
209.72 | Secondary neuroendocrine tumor of liver | C7B.02 | Secondary carcinoid tumors of liver |
230.0 | Carcinoma in situ of lip, oral cavity, and pharynx | D00.00 - D00.08 | Carcinoma in situ of lip, oral cavity, and pharynx |
232.0 | Carcinoma in situ of skin of lip | D04.0 | Carcinoma in situ of lip |
232.1 | Carcinoma in situ of eyelid, including canthus | D04.10 - D04.122 | Carcinoma in situ of skin of eyelid, including canthus |
232.2 | Carcinoma in situ of skin of ear and external auditory canal | D04.20 - D04.22 | Carcinoma in situ of skin of ear and external auricular canal |
232.3 | Carcinoma in situ of skin of other and unspecified parts of face | D04.30 - D04.39 | Carcinoma in situ of skin of other and unspecified parts of face |
232.4 | Carcinoma in situ of scalp and skin of neck | D04.4 | Carcinoma in situ of skin of scalp and neck |
250.00, 250.10, 250.20, 250.30, 250.40, 250.50, 250.60, 250.70, 250.80, 250.90 | Type II or unspecified diabetes mellitus, not stated as uncontrolled code range NOTE: Fifth-digit 0 is not used for type II patients, even if the patient requires insulin. Use additional code (V58.67), if applicable, for associated long-term (current) insulin use. | E11.00 - E11.9 | Type II diabetes mellitus |
250.02, 250.12, 250.22, 250.32, 250.42, 250.52, 250.62, 250.72, 250.82, 250.92 | Type II or unspecified diabetes mellitus, uncontrolled code range (added 01-06-2004) NOTE: Fifth-digit 2 is used for type II patients, even if the patient requires insulin. Use additional code (V58.67), if applicable, for associated long-term (current) insulin use. | E11.00, E11.01, E11.21, E11.311, E11.319 E11.36, E11.39, E11.40 E11.51, E11.65, E11.69, E11.8 | Type II diabetes mellitus, uncontrolled |
E11.3521 - E11.3529 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula | ||
E11.3531 - E11.3539 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula | ||
E11.3541 - E11.3549 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment | ||
E11.37X1 - E11.37X9 | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment | ||
E13.37X1 - E13.37X9 | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment | ||
250.03, 250.13, 250.23, 250.33, 250.43, 250.53, 250.63, 250.73, 250.83, 250.93 | Type I diabetes mellitus, uncontrolled code range | E10.10, E10.11, E10.21, E10.311, E10.319, E10.36, E10.39, E10.40, E10.51 E10.65, E10.69, E10.8 | Type I diabetes mellitus, uncontrolled |
E10.3521 - E10.3529 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula | ||
E10.3531 - E10.3539 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula | ||
E10.3541 - E10.3549 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment | ||
E10.37X1 - E10.37X9 | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment | ||
334.1 | Hereditary spastic paraplegia | G11.4 | Hereditary spastic paralegia |
336.1 | Vascular myelopathies | G95.11 | Acute infarction of spinal cord (embolic) (nonembolic) |
G95.19 | Other vascular myelopathies | ||
340 | Multiple sclerosis | G35, G35.A, G35.B0, G35.B1, G35.B2, G35.C0, G35.C1, G35.C2, G35.D | Multiple sclerosis (G35.A, G35.B0, G35.B1, G35.B2, G35.C0, G35.C1, G35.C2, G35.D New 10/01/2025) (G35 Deleted 09/30/2025) |
342.10 - 342.12 | Spastic hemiplegia code range | G81.10 - G81.14 | Spastic hemiplegia code range |
343.0 - 343.9 | Infantile cerebral palsy code range | G80.0, G80.1, G80.2, G80.4, G80.8, G80.9 | Cerebral palsy (infantile) |
344.1 | Paraplegia | G82.20 - G82.22 | Paraplegia |
344.61 | Cauda equina syndrome with neurogenic bladder | G83.4 | Cauda equina syndrome |
344.81 | Locked-in state | G83.5 | Locked-in state |
344.89 | Other specified paralytic syndrome | G83.81 - G83.89 | Other specified paralytic syndromes |
345.60 | Infantile spasms without mention of intractable epilepsy | G40.401, G40.409, G40.821, G40.822 | Other generalized epilepsy and epileptic syndromes, not intractable |
345.61 | Infantile spasms with intractable epilepsy | G40.411, G40.419, G40.823, G40.824 | Other generalized epilepsy and epileptic syndromes, intractable |
435.0, 435.1, 435.3, 435.8, 435.9 | Transient cerebral ischemia code range | G45.0, G45.1, G45.2, G45.8, G45.9 | Transient cerebral ischemia code range |
CPT copyright American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.